The neurology sector saw two mid‑late stage setbacks over the holidays. Nido Biosciences closed after its lead neurologic candidate failed to show meaningful benefit in a phase 2 study, prompting the company to wind down operations. Biohaven reported a failed phase 2 trial of BHV‑7000 in major depressive disorder and said it will not run further psychiatric studies as it refocuses on immunology, obesity and a pending pivotal epilepsy readout. Analysts flagged execution and CNS exposure questions for the class.